Association Between ApoA1 Gene Polymorphisms and Antipsychotic Drug-Induced Dyslipidemia in Schizophrenia

Overview

Journal Neuropsychiatr Dis Treat

Publisher Dove Medical Press

Specialty Psychiatry

Date 2021 May 7

PMID 33958870

Citations 3

Authors

Lin Fan

Yiwen You

Yao Fan

Chong Shen

Yong Xue

Affiliations

Soon will be listed here.

Abstract

Purpose: Dyslipidemia frequently occurs in schizophrenia patients treated with antipsychotic drugs (APDs), especially atypical APDs. Apolipoprotein A1 (ApoA1) plays a key role in lipid metabolism. The aim of this study was to investigate whether ApoA1 gene polymorphisms are associated with APD-induced dyslipidemia in schizophrenia patients.

Patients And Methods: A total of 1987 patients with schizophrenia were enrolled in this study. Serum lipid profiles were determined with a biochemistry analyzer. Genotyping for the rs5072 polymorphism of ApoA1 was performed with TaqMan assay. Logistic regression analysis was carried out to evaluate the relationship between ApoA1 gene polymorphisms and APD-induced dyslipidemia. The effects of drug classification (typical vs atypical APD) and drug regimen (monotherapy vs combination therapy) on serum lipid levels were also analyzed.

Results: A significant association was found between rs5072 and triglyceride (TG) levels in the recessive model of the logistic regression analysis (adjusted odds ratio [OR]=1.50, 95% confidence interval [CI]: 1.03, 2.17; P<0.05). TG level was significantly higher in patients treated with combination therapy (1.03 (0.71, 1.51) mmol/l) compared to monotherapy (0.93 (0.67, 1.43) mmol/l) and was also associated with sex. There were significant differences in TG levels among the three genotypes of ApoA1 rs5072 (GG, GA, and AA) in the whole study population and in patients treated with atypical APDs.

Conclusion: The ApoA1 rs5072 variant is associated with dysregulated TG metabolism in schizophrenia patients treated with APDs, which may increase susceptibility to dyslipidemia.

Citing Articles

Genome-wide association study implicates lipid pathway dysfunction in antipsychotic-induced weight gain: multi-ancestry validation.

Liao Y, Yu H, Zhang Y, Lu Z, Sun Y, Guo L Mol Psychiatry. 2024; 29(6):1857-1868.

PMID: 38336841 DOI: 10.1038/s41380-024-02447-2.

Genetic study of the causal effect of lipid profiles on insomnia risk: a Mendelian randomization trial.

Gong Q, Guo C BMC Med Genomics. 2023; 16(1):325.

PMID: 38087303 PMC: 10714578. DOI: 10.1186/s12920-023-01761-y.

Crosstalk between Schizophrenia and Metabolic Syndrome: The Role of Oxytocinergic Dysfunction.

Goh K, Chen C, Wu T, Chen C, Lu M Int J Mol Sci. 2022; 23(13).

PMID: 35806096 PMC: 9266532. DOI: 10.3390/ijms23137092.

References

Xu L, Zhou Y, Yao J, Sun S, Rui Q, Yang X . Apolipoprotein A1 polymorphisms and risk of coronary artery disease: a meta-analysis. Arch Med Sci. 2017; 13(4):813-819. PMC: 5510497. DOI: 10.5114/aoms.2017.65233. View

Stefansson H, Ophoff R, Steinberg S, Andreassen O, Cichon S, Rujescu D . Common variants conferring risk of schizophrenia. Nature. 2009; 460(7256):744-7. PMC: 3077530. DOI: 10.1038/nature08186. View

Zhang J, Gallego J, Robinson D, Malhotra A, Kane J, Correll C . Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2012; 16(6):1205-18. PMC: 3594563. DOI: 10.1017/S1461145712001277. View

Wu R, Zhao J, Zhai J, Guo X, Guo W . Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. J Clin Psychopharmacol. 2007; 27(4):374-9. DOI: 10.1097/JCP.0b013e3180cac8db. View

Correll C, Frederickson A, Kane J, Manu P . Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. Schizophr Res. 2006; 89(1-3):91-100. PMC: 2718048. DOI: 10.1016/j.schres.2006.08.017. View

Wu R, Zhao J, Liu Z, Zhai J, Guo X, Guo W . Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl). 2006; 186(4):572-8. DOI: 10.1007/s00213-006-0384-5. View

Suarez-Sanchez F, Klunder-Klunder M, Valladares-Salgado A, Gomez-Zamudio J, Peralta-Romero J, Meyre D . APOA5 and APOA1 polymorphisms are associated with triglyceride levels in Mexican children. Pediatr Obes. 2016; 12(4):330-336. DOI: 10.1111/ijpo.12147. View

Insel T . Rethinking schizophrenia. Nature. 2010; 468(7321):187-93. DOI: 10.1038/nature09552. View

Tandon R, Keshavan M, Nasrallah H . Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology. Schizophr Res. 2008; 102(1-3):1-18. DOI: 10.1016/j.schres.2008.04.011. View

10.

Vlad C, Foia L, Popescu R, Ivanov I, Luca M, Delianu C . Apolipoproteins A and B and PCSK9: Nontraditional Cardiovascular Risk Factors in Chronic Kidney Disease and in End-Stage Renal Disease. J Diabetes Res. 2020; 2019:6906278. PMC: 6931031. DOI: 10.1155/2019/6906278. View

11.

Wu X, Huang Z, Wu R, Zhong Z, Wei Q, Wang H . The comparison of glycometabolism parameters and lipid profiles between drug-naïve, first-episode schizophrenia patients and healthy controls. Schizophr Res. 2013; 150(1):157-62. DOI: 10.1016/j.schres.2013.07.051. View

12.

Lieberman J . Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry. 1999; 46(6):729-39. DOI: 10.1016/s0006-3223(99)00147-x. View

13.

Seeman M . Secondary effects of antipsychotics: women at greater risk than men. Schizophr Bull. 2008; 35(5):937-48. PMC: 2728808. DOI: 10.1093/schbul/sbn023. View

14.

Jeon S, Kim Y . Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome. Int J Mol Sci. 2017; 18(10). PMC: 5666855. DOI: 10.3390/ijms18102174. View

15.

Leucht S, Corves C, Arbter D, Engel R, Li C, Davis J . Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2008; 373(9657):31-41. DOI: 10.1016/S0140-6736(08)61764-X. View

16.

Qiu H, He Y, Zhang Y, He M, Liu J, Chi R . Antipsychotic polypharmacy in the treatment of schizophrenia in China and Japan. Aust N Z J Psychiatry. 2018; 52(12):1202-1212. DOI: 10.1177/0004867418805559. View

17.

La Y, Wan C, Zhu H, Yang Y, Chen Y, Pan Y . Decreased levels of apolipoprotein A-I in plasma of schizophrenic patients. J Neural Transm (Vienna). 2006; 114(5):657-63. DOI: 10.1007/s00702-006-0607-2. View

18.

Miyamoto S, Miyake N, Jarskog L, Fleischhacker W, Lieberman J . Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry. 2012; 17(12):1206-27. DOI: 10.1038/mp.2012.47. View

19.

Zhang J, Malhotra A . Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol. 2010; 7(1):9-37. PMC: 3057913. DOI: 10.1517/17425255.2011.532787. View

20.

Omamurhomu Olose E, Edet J, Igwe M, Chukwujekwu D, Aguocha M, Uwakwe R . Dyslipidaemia and Medical Outcome (Health Related Quality of Life) in Patients with Schizophrenia Taking Antipsychotics in Enugu, Nigeria. Psychiatry J. 2017; 2017:9410575. PMC: 5337880. DOI: 10.1155/2017/9410575. View